NABOTA
LIVE

Serial Number

88938201

Owner

DAEWOONG PHARMACEUTICAL CO., LTD.

Attorney

John M. Kim

Filing Date

May 28, 2020

Add to watchlist:

No watchlists yet
View on USPTO

NABOTA Trademark

Serial Number: 88938201 • Registration: 6383994

NABOTA is a trademark filed by DAEWOONG PHARMACEUTICAL CO., LTD. on May 28, 2020. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

DAEWOONG PHARMACEUTICAL CO., LTD. (12 trademarks)

35-14, Jeyakgongdan 4-gil,

Entity Type: 03

Trademark Details

Filing Date

May 28, 2020

Registration Date

June 15, 2021

Published for Opposition

March 30, 2021

Goods & Services

Botulinum toxin for medical use for use in the treatment of glabellar lines, muscular rigidity, blepharospasm, cervical dystonia, hyperhidrosis, strabismus, prostate disorder, migraine headache, urge incontinence, urinary retention that is secondary to a hypertrophied bladder neck, recalcitrant voiding dysfunction, urge incontinence, neurogenic bladder dysfunction and pelvic pain; Pharmaceutical preparations, namely, acne medications, acne treatment preparations, adrenal hormone preparations, alcohol for topical use, allergy and allergy relief medications, analgesics, androgen preparations, anesthetics for surgical and non-surgical use, antacids, bactericides, antiarrhythmics, antibiotics, anticoagulants, anticonvulsants, antidepressants, antidiabetic preparations, antivirals, anti-cancer preparations, anti-infectives, anti-inflammatories, antipyretics, antibacterial pharmaceuticals, calcium channel blockers, beta blockers, chemical compounds for drug delivery, eye drops, eye patches for medical purposes, hair growth stimulants, vaccines, vaccine adjuvants, vaccine stabilizers, diuretics, amino acids for medical purposes; Medicines for the treatment of gastrointestinal diseases; chemical preparations for pharmaceutical purposes for the treatment of glabellar lines, muscular rigidity, blepharospasm, cervical dystonia, hyperhidrosis, strabismus, prostate disorder, migraine headache, urge incontinence, urinary retention that is secondary to a hypertrophied bladder neck, recalcitrant voiding dysfunction, urge incontinence, neurogenic bladder dysfunction, and pelvic pain; chemico-pharmaceutical preparations for the treatment of glabellar lines, muscular rigidity, blepharospasm, cervical dystonia, hyperhidrosis, strabismus, prostate disorder, migraine headache, urge incontinence, urinary retention that is secondary to a hypertrophied bladder neck, recalcitrant voiding dysfunction, urge incontinence, neurogenic bladder dysfunction, and pelvic pain. drugs for medical purposes for the treatment of glabellar lines, muscular rigidity, blepharospasm, cervical dystonia, hyperhidrosis, strabismus, prostate disorder, migraine headache, urge incontinence, urinary retention that is secondary to a hypertrophied bladder neck, recalcitrant voiding dysfunction, urge incontinence, neurogenic bladder dysfunction, and pelvic pain; Medicines for human purposes for the treatment of glabellar lines, muscular rigidity, blepharospasm, cervical dystonia, hyperhidrosis, strabismus, prostate disorder, migraine headache, urge incontinence, urinary retention that is secondary to a hypertrophied bladder neck, recalcitrant voiding dysfunction, urge incontinence, neurogenic bladder dysfunction, and pelvic pain; pharmaceutical preparations for activating cellular function; Adjuvants for medical purposes; pharmaceutical preparations for central nerve treatment, namely, for the treatment of sequelae caused by damage to the central nerve in the brain; dermatological pharmaceutical products, namely, injectable botulinum toxin for refining wrinkles; pharmaceutical preparations for treating skin disorders; antibiotic preparations; pharmaceutical preparations for chemical disorder treatment, namely, for treatment of chemical imbalance in the brain

Filing History

COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Jun 15, 2026 REM1
REGISTERED-PRINCIPAL REGISTER
Jun 15, 2021 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 30, 2021 NPUB
PUBLISHED FOR OPPOSITION
Mar 30, 2021 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 10, 2021 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 22, 2021 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 1, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 1, 2021 CRFA
ASSIGNED TO LIE
Jan 27, 2021 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 15, 2020 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Aug 28, 2020 GNRN
NON-FINAL ACTION E-MAILED
Aug 28, 2020 GNRT
NON-FINAL ACTION WRITTEN
Aug 28, 2020 CNRT
ASSIGNED TO EXAMINER
Aug 28, 2020 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 17, 2020 NWOS
NEW APPLICATION ENTERED
Jun 1, 2020 NWAP